6% of patients claimed to be fully adherent during the last week. The major source of motivation to take medication was expectation to lower cholesterol level, and only extremely infrequently (2.7%) – to prolong life. Patients often pointed at economic constrains as a reason for low adherence. Getting information from doctor about the purpose of buy 3-MA therapy (OR=3.04, 95%CI 1.36-6.80, P < 0.01), understanding the purpose of therapy

(OR=5.09, 95%CI 1.30-19,90, P < 0.05), reading the patient information leaflet (OR=3.37, 95%CI 1.78-6.36, P < 0.001), positive opinion about the effectiveness of the treatment (OR=2.45, 95%CI 1.24-4.81, P < 0.01), and visiting primary care once a month (OR=2.22, 95%CI 1.05-4.69, P < 0.05) were associated with adherence to the treatment.

Non-adherence to lipid-lowering medication is a frequent problem. This study suggests that effective doctor-patient communication may play an important role in rising patients’ motivation to systematic treatment. Better adherence might be also obtained with prescribing more affordable drugs.”
“The degradation characteristics of PPCPs commonly found in surface water under

UV treatment were examined for 30 kinds of PPCPs using a UV/Lamp1 see more that emits light at a wavelength of 254 nm and a UV/Lamp2 that emits light at 254 nm and 185 nm in pure water. When a UV dose of some 230 mJ/cm(2) was introduced to the 30 PPCPs, photodegradation rates of about >3% (theophylline) to 100% (diclofenac) and about>15% (clarithromycin) to 100% (diclofenac) were observed for UV/Lamp1 and UV/Lamp2, respectively. This Selleckchem Anlotinib study also showed that UV/Lamp2, which photolyzes water molecules and generates OH radicals, is more effective for PPCP removal than UV/lamp1. It was postulated that the degradation rates of sulfamethoxazole, sulfamonomethoxine, sulfadimethoxine and sulfadimidine, all, including sulfamethoxazole, derived from sulfanilamide, under UV/Lamp1 resulted mainly from the bond-breaking reactions occurring between -SO(2)- and its side atoms, the C-S bond and the N-H bond. Some PPCPs with amide bonds, such as cyclophosphamide

and DEET, were highly resistant to photodegradation by UV/Lamp1. AOPs (Advanced oxidation processes) such as the UV/H(2)O(2) or UV/O(3) processes should therefore be considered for their potential to remove these substances effectively. (C) 2009 Elsevier Ltd. All rights reserved.”
“Pharmacogenetics in cardiovascular medicine brings the potential for personalized therapeutic strategies that improve efficacy and reduce harm. Studies evaluating the impact of genetic variation on pharmacologic effects have been undertaken for most major cardiovascular drugs, including antithrombotic agents, -adrenergic receptor blockers, statins, and angiotensin-converting enzyme inhibitors. Across these drug classes, many polymorphisms associated with pharmacodynamic, pharmacokinetic, or surrogate outcomes have been identified.